Cardinal Health Inc
CAH: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|?> | LOCK|T#B^ | LOCK|PJ&Wq# |
Cardinal Wraps Up Fiscal 2026 With Revenue Softness but Margin Expansion and Earnings Growth Impress
Business Strategy and Outlook
Cardinal Health is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $230 billion in US drug distribution sales in fiscal 2026, Cardinal supplies roughly one-fourth of the overall market. Its two closest competitors are Cencora and McKesson, and together they operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
